Diabetic nephropathy encompasses several structural alterations including renal hypertrophy, thickening of basement membranes and progressive glomerular accumulation of extracellular matrix components [1±3]. Expansion of the glomerular mesangium occurs within weeks of the onset of experimental Type I (insulindependent) diabetes mellitus and correlates closely with the deterioration in glomerular function [1±3]. Cell culture studies using mesangial cells exposed to high glucose concentration medium as well as in vivo investigations in various models of diabetes suggest a biphasic growth response: there is a very early and self-limited proliferation of mesangial cells with subsequent cell cycle arrest in the G 1 -phase and concomitant hypertrophy [4±6]. We and others have previ- Diabetologia (1999) Results. Glomerular expression of all three cyclindependent kinase inhibitors were stimulated in BBdp rats compared with non-diabetic BBdr animals. Enalapril treatment for 3 weeks, started after the onset of diabetes, reduced the glomerular expression of p16 INK4 and p27 Kip1 but not of p21 Cip1 . Enalapril also prevented the increase in kidney weights observed in BBdp rats but had no effect on systolic blood pressure or glucose concentrations. Conclusion/interpretation. Our data show that enalapril attenuates the glomerular expression of cyclindependent kinase inhibitors in diabetes and suggest a molecular mechanism of how angiotensinconverting enzyme inhibitors prevent renal hypertrophy in diabetes. [Diabetologia (1999 
ously described that this G 1 -phase arrest is principally mediated by inhibitors of cyclin-dependent kinases (Cdk) such as p27 Kip1 and p21 Cip1 [7±9] . High glucose stimulates expression of these small proteins [7] . Because angiotensin converting enzyme (ACE) inhibitors prevent glomerular hypertrophy and slow progression of diabetic nephropathy in many models as well as in humans suffering from diabetes [10±14], our study was undertaken to test a potential influence of the ACE inhibitor enalapril on the glomerular expression of cyclin-dependent kinase inhibitors in BBdp rats, an animal model of spontaneous Type I diabetes [15] .
Material and methods
Rats. A breeding colony of BBdp and BBdr rats was established in our animal facility. Because the onset of diabetes is sudden in BBdp rats and occurs at about 60±100 days of age [15±19], urine was screened daily by dip sticks starting at age 55 days. If the urine showed a positive reaction for glucose for 3 consecutive days, blood was drawn from the tail to confirm hyperglycaemia. Blood glucose concentrations were measured with B-glucose analyser (HemoCue, ¾ngelholm, Sweden). Hyperglycaemic BBdp rats received subcutaneously a sustained release insulin implant (Lindplant, Linshin, Ontario, Canada; releases 2 units insulin per 24 h). This treatment prevents the development of overt ketosis and death but does not render the animals normoglycaemic. To control for potential confounding sex effects, only male rats were used. After onset of diabetes, BBdp rats were allocated at random into two groups either receiving normal tap water or water supplemented with 100 mg enalapril (Sigma, Deisenhofen, Germany) per litre water for 3 weeks. Age-matched BBdr rats which do not develop diabetes were treated for 3 weeks with tap water and served as controls [19] . Water intake for BBdp rats was approximately 70 ml/day. Thus, these animals received roughly 23 mg enalapril per kg body weight per day. Non-diabetic BBdr rats drank 30 ml water per day. After 3 weeks, systolic blood pressure was measured in slightly restrained rats by tail plethysmography. Animals were weighed and anaesthetized. Blood was drawn by puncture of the aorta, kidneys were removed, wet weight was determined and kidneys were kept on ice until further processing. A slice of each kidney was fixed in Methyl Carnoy's solution for immunohistochemistry. All animal experiments were approved by the local government and were done according to the ªprinciples of laboratory animal careº (NIH publication No. 86±23, 1985) . Five to eight animals were investigated in each group.
Western blots. Glomeruli were separately isolated from each animal by differential sieving using techniques established for this laboratory [8] . Final preparations contained more than 95 % glomeruli as judged by light microscopy. Isolated glomeruli were directly lysed on ice in 300 ml of a buffer containing 2 % SDS and 60 mmol/l TRIS-HCl (pH 6.8) supplemented with a cocktail of protease inhibitors (Complete, Boehringer Mannheim, Germany; contains antipain-HCl, chymostatin, leupeptin, bestatin, pepstatin, phosphoramidon, aprotinin, EDTA). After centrifugation, the supernatants were transferred to new tubes and protein contents were measured by a modification of the Lowry method. Protein concentrations were adjusted to 60 mg/sample and 5 % glycerol/0.03 % bromophenol blue/10 mmol/l dithiothreitol were added, then samples were boiled for 5 min. After centrifugation, supernatants were loaded onto a denaturing 8 % SDS polyacrylamide gel. Low molecular weight markers (Rainbow markers; Amersham, Braunschweig, Germany), which comprise 2350 to 45 000 Daltons served as the molecular weight standards. After completion of electrophoresis, proteins were electroblotted onto a nitrocellulose membrane (High-bond-N, Amersham) in transfer buffer (50 mmol/l TRIS-HCl [pH 7.0], 380 mmol/l glycine, 0.1 % SDS, 20 % methanol). Filters were stained with Ponceau S to control for equal loading and transfer. The blots were blocked in 5 % non-fat dry milk in PBS with 0.1 % Tween 20 for 1 h at 22°C. For the detection of p27 Kip1 , a mouse monoclonal anti-human p27
Kip1 antibody was obtained from Transduction Laboratories (Lexington, Mass., USA). This antibody reacts with rat p27 Kip1 . The p21
Cip1 protein expression was detected with a mouse monoclonal anti-human p21
Cip1 antibody having cross-reactivity with the murine protein (Dako, Glostrup, Denmark). These primary antibodies were used in a 1:1000 dilution. The p16 INK4 was detected with mouse antihuman p16
INK4 monoclonal antibody (Pharmingen, Hamburg, Germany). The p16 INK4 antibody was used in a 1:500 dilution. Although this antibody has not been previously examined for cross-reactivity, it reacted with a 16 kDa protein in our experiments suggesting that this antibody detects rat p16
INK4
. To further test the specificity of this antibody, a 1:200 dilution of this antibody was incubated with 10 mg of recombinant human p16 INK4 GST fusion protein (Pharmingen) for 30 min. After centrifugation, the supernatant was used for western blot detection and showed no specific binding to the 16 kDa rat protein anymore suggesting specific depletion by the exogenous antigen (data not shown). Washes, incubations with horseradish peroxidase-conjugated anti-mouse secondary antibodies and detection using the ECL reagent (Amersham) were done according to the manufacturer's recommendations. To control for small variations in protein loading and transfer, membranes were washed and reincubated with a mouse monoclonal antib-actin antibody (Sigma). Incubation with secondary antibody and detection was done as described above. Exposed films were scanned with Fluor-S multi-imager (Bio-Rad laboratories, Hercules, USA) and data were analysed with the computer program Multi-Analyst from Bio-Rad. A ratio of the intensities of the bands for p16 INK4 , p27 Kip1 , p21
Cip1 and b-actin was calculated [7, 8] . Western blots were independently repeated three times with qualitatively similar results.
Immunohistochemistry. We prepared two mm thick paraffin sections. To show the immunohistochemistry of p27 Kip1 , sections were dewaxed, rehydrated and microwave pretreated. Tissue sections were incubated with a 1:20 dilution of the mouse monoclonal anti-p27
Kip1 antibody. As additional controls, slides were incubated with normal mouse serum. The alkaline phosphatase-antialkaline phosphatase (APAAP) complex was used to make the primary antibody visible as previously described [8] . Evaluation of p27 Kip1 -positive cells was done by an investigator blinded to the experimental protocol. Glomerular cells expressing p27 Kip1 were counted in at least 15 glomeruli from each rat.
Statistical analysis. All values are presented as means ± SEM. Statistical significance among multiple groups was tested with non-parametric Kruskal-Wallis test. Individual groups were then tested using the Wilcoxon Mann-Whitney test. A p value of less than 0.05 was considered significant. Table 1 shows body weight, renal weights, blood glucose concentrations and systolic blood pressure at the end of the experimental protocol after 3 weeks. Although BBdp rats and BBdp rats treated with enalapril received insulin pellets to prevent ketoacidosis and premature death, blood glucose concentrations were still considerably higher compared with non-diabetic BBdr animals. Enalapril had no influence of blood glucose concentrations. Diabetic BBdp rats had a higher kidney weight than the BBdr group. Enalapril treatment reduced this increase in weight. In accordance with previous studies, diabetic BBdp animals had a similar systolic blood pressure as non-diabetic BBdr rats [15, 16] . Although enalapril treatment numerically reduced systolic blood pressure in BBdp rats compared with untreated animals, these values failed to reach statistical significance. (Table 1) . Figure 1 shows a western blot of glomerular lysates incubated with an antibody against p27 Kip1 . The blot was re-incubated with an antibody against b-actin to control for small variations in protein loading and transfer. Glomeruli obtained from non-diabetic BBdr rats had almost no expression of p27
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Kip1 protein. In contrast, BBdp rats exhibited a significantly higher expression of p27 Kip1 , although there was some variation between individual rats (BBdr: 1.00 ± 0.05, BBdp: 3.72 ± 0.2 relative changes in p27
Kip1 expression normalised to b-actin, p < 0.01, n = 5). Enalapril treatment of BBdp rats significantly reduced glomerular p27
Kip1 protein expression compared with the untreated group (BBdp + enalapril: 0.89 ± 0.04 relative changes in p27
Kip1 expression normalised to b-actin, p < 0.01 vs untreated BBdp rats, n = 5). Expression of p21
Cip1 was differentially regulated (Fig. 2) . Although there was a greater variation of glomerular p21
Cip1 expression among individual animals with one BBdr rat having a high concentration and two diabetic BBdp animals with rather low expression, overall expression was also significantly higher in diabetic rats (BBdr: 1.00 ± 0.02, BBdp:
Cip1 expression normalised to b-actin, p < 0.05, n = 5). Enalapril treatment failed, however, to reduce glomerular p21 Cip1 expression in BBdp rats (BBdp + enalapril: 4.5 ± 0.1 relative changes in p21
Cip1 expression normalized to b-actin, not significant vs untreated BBdp rats, n = 5). Base line p16
INK4 expression in non-diabetic BBdr rats was somewhat higher compared with p27
Kip1 and p21 Cip1 concentrations (Fig. 3) . Glomerular p16
INK4 expression was significantly increased in BBdp rats and was attenuated by enalapril treatment ( Fig. 3 ; BBdr: 1.0 ± 0.4, BBdp: 5.1 ± 0.9*, BBdp + enalapril: 1.6 ± 0.2 + relative changes in p16
INK4 expression normalised to b-actin, *p < 0.01 vs BBdr, + p < 0.01 vs BBdp, n = 6 for BBdr, n = 8 for BBdp, n = 4 for BBdp + enalapril). To further confirm that enalapril attenuates glomerular p27
Kip1 expression, immunohistochemistry staining was done and positive cells were counted by an investigator blinded to the experimental protocol. Because the majority of cells expressing p27
Kip1 in the normal rat glomerulus are podocytes [8, 20] and it can be occasionally difficult to unambiguously decide to what exact type a positive glomerular cell belongs, we counted all glomerular cells expressing p27 Kip1 . As shown in Fig. 4 A-C, the number of total glomerular cells expressing p27
Kip1 was significantly increased in BBdp rats compared with BBdr animals (BBdr:
Kip1 positive cells (BBdp + enalapril: 21.0 ± 1.6 positive cells per glomerulus, p < 0.001 vs untreated BBdp rats, at least 15 glomeruli counted from each rat, n = 5).
Discussion
Renal hypertrophy occurs early after the onset of diabetes mellitus and precedes the development of glomerulosclerosis [1, 2, 21] . Experiments in different animal models of diabetes as well as studies in humans have provided convincing evidence that ACEinhibitor treatment could prevent and even partly reverse renal hypertrophy [10±13]. Although a restoration to normal of glomerular hyperfiltration, which possibly activates through mechanical stretch mesangial and endothelial growth processes, could account for this effect, there is increasing evidence that angiotensin II (ANG II) exerts direct growth stimulatory effects on glomerular cells which could be further en- . This blot is representative of three experiments with qualitatively similar results. Lanes 1±5: non-diabetic BBdr rats, lanes 6±10: diabetic BBdp rats, lane 11±15: diabetic BBdp after receiving enalapril for 3 weeks [20] , it is occasionally difficult to unambiguously decide whether glomerular cells staining positive for p27
Kip1 are indeed of mesangial origin. Therefore, we decided to count all positive glomerular cells and expression was clearly increased in diabetic BBdp rats and attenuated by enalapril treatment. Overexpression of Cdk inhibitors such as p16 INK4 and p21 Cip1 reduces proliferation but stimulates cellular hypertrophy of various cultured renal cells [29] . Thus, induction of Cdk inhibitors appears to be the pivotal underlying molecular mechanism for the development of cell hypertrophy.
Enalapril clearly reduced in our study the increased kidney weights in BBdp rats to values of non-diabetic BBdr controls. Although total kidney weight is only a rather crude measure of hypertrophy, these findings provide a correlation between compensatory hypertrophy and the expression of p16 INK4 and p27
Kip1 in the enlarging kidney. Although we have previously shown in cultured mesangial cells that high glucose concentration alone is sufficient to stimulate p27
Kip1 expression [7] , enalapril did not reduce hyperglycaemia in BBdp rats suggesting that other mechanisms than a simple decrease in blood glucose concentration must underlie the enalapril-mediated reduction in p27
Kip1 positive cells. In accordance with previous investigations, diabetic BBdp rats are not hypertensive compared with their non-diabetic littermates [16±19]. Thus, it is unlikely that an enalapril-mediated reduction in systemic blood pressure contributed to the decrease in glomerular p27
Kip1 expression. BBdp rats show glomerular hyperfiltration [18] and we cannot therefore rule out that a normal in glomerular filtration rate caused by the ACE inhibitor is involved in attenuated p27 Kip1 expression. We would, however, like to propose a more direct effect of ANG II in the induction of p27 Kip1 expression. BBdp rats have an activated renin-angiotensin system (RAS) because it has been previously shown that renin secretion is stimulated in this rat strain [16] . Furthermore, an increase in urinary endothelin excretion could additionally provide an indirect hint to an activated RAS because ANG II stimulates renal endothelin synthesis [30] . We have previously shown in proximal tubular cells that ANG II stimulates expression of p27 Kip1 and that this induction is associated with G 1 -phase arrest and cellular hypertrophy [31] . Intracellular reactive oxygen species, produced by an ANG II-mediated induction of membrane NADPH oxidase activity, are important signalling intermediates in the increase in p27
Kip1 expression [32] . We have preliminary evidence that oxygen radicals activate mitogenactivated protein (MAP) kinases which in turn directly phosphorylate p27
Kip1 leading to an increase in expression (Hannken and Wolf, unpublished observations). Because the intrarenal RAS is activated in BBdp rats, it is possible that ANG II directly stimulates p27
Kip1 expression. Enalapril interferes with ANG II generation, explaining the attenuation of p27 Kip1 expression. Increased oxidative stress is enhanced in the diabetic environment [33] and could further stimulate p27
Kip1 expression. Notably, it has been reported that enalaprilat has direct antioxidant effects in cultured mesangial cells and inhibits hydrogen peroxide formation induced by high glucose concentrations in these cells [34] . This action is not linked to ACE inhibition [34] . Thus, enalapril could interfere with oxygen radical formation and prevent by this mechanism the induction of p27 Kip1 . Notably, p21
Cip1 expression, albeit previously shown to be stimulated in diabetic glomeruli [9] , was not reduced by enalapril treatment. It has been previously shown that p21
Cip1 , in contrast to p27
Kip1
, can be transcriptionally induced by a p53-dependent mechanism [35] . One possible explanation for the differential regulation could be that p21
Cip1 expression depends more on the diabetic environment such as ambient high glucose concentration and not so much on a locally activated RAS.
The p16 INK4 is the prototype of the INK4 family of Cdk inhibitors and members of this family differ in both structure and mechanism of action. In contrast to p21 Cip1 Kip1 expression.
Several observations convincingly indicate that the development of irreversible glomerulosclerosis in diabetes is always preceded by the early renal hypertrophy [39] . It is debatable whether or not these hypertrophic processes will inevitably lead to irreversible fibrotic changes in humans but experimental animal models provide ample evidence that this is the case [39] . Treatment with ACE inhibitor prevents kidney hypertrophy and slows the progression of renal disease.
In summary, short-term ACE-inhibitor treatment for 3 weeks prevented compensatory renal hypertrophy and the stimulated glomerular expression of the Cdk-inhibitors, p16 INK4 and p27 Kip1 in BBdp rats, an autoimmune model of Type I diabetes. Although p21
Cip1 was also increased in glomeruli of diabetic animals, enalapril failed to reduce the expression of this Cdk inhibitor. Our results provide an insight into the molecular mechanism of how ACE inhibitors possibly modify renal hypertrophy and slow the progression of renal disease in diabetes. 
